Evidence map›Paper›PMID 36681700›Full record

ArticleScientific reports2023

Current tobacco use and COVID-19 diagnoses in a cohort of adult clients of public dental clinics in Sweden.

M R Galanti, F Andersson, I H Caspersen, S Peña, S Karvonen, P Magnus, E Raffetti, N Orsini, C Magnusson, A N Shaaban and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

M R GalantiDepartment of Global Public Health, Karolinska Institutet, 171 77, Stockholm, Sweden. rosaria.galanti@ki.se.
F AnderssonDepartment of Global Public Health, Karolinska Institutet, 171 77, Stockholm, Sweden.
I H CaspersenCentre for Fertility and Health, Norwegian Institute of Public Health, Skøyen, Postbox 222, 0213, Oslo, Norway.
S PeñaFinnish Institute for Health and Welfare, Postbox 30, 00271, Helsinki, Finland.
S KarvonenFinnish Institute for Health and Welfare, Postbox 30, 00271, Helsinki, Finland.
P MagnusCentre for Fertility and Health, Norwegian Institute of Public Health, Skøyen, Postbox 222, 0213, Oslo, Norway.
E RaffettiDepartment of Global Public Health, Karolinska Institutet, 171 77, Stockholm, Sweden.
N OrsiniDepartment of Global Public Health, Karolinska Institutet, 171 77, Stockholm, Sweden.
C MagnussonDepartment of Global Public Health, Karolinska Institutet, 171 77, Stockholm, Sweden.
A N ShaabanDepartment of Global Public Health, Karolinska Institutet, 171 77, Stockholm, Sweden.
M P HergensUnit for Communicable Disease Control, Postbox 6909, 102 39, Stockholm Region, Sweden.
P SkottDepartment of Orofacial Medicine, Folktandvården Stockholm, Postbox 6420, 113 82, Stockholm, Sweden.
Karolinska Institutet · SEFinnish Institute for Health and Welfare · FINorwegian Institute of Public Health · NOPublic Dental Service Västra Götaland · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smoking has been linked with both increased and decreased risk of COVID-19, prompting the hypothesis of a protective role of nicotine in the pathogenesis of the disease. Studies of the association between use of smokeless tobacco and COVID-19 would help refining this hypothesis. We analysed data from 424,386 residents in the Stockholm Region, Sweden, with information on smoking and smokeless tobacco (snus) use prior to the pandemic obtained from dental records. Diagnoses of COVID-19 between February and October 2020 were obtained from health-care registers. We estimated the risk of receiving a diagnosis of COVID-19 for current smokers and for current snus users relative to non-users of tobacco, adjusting for potential confounders (aRR). The aRR of COVID -19 was elevated for current snus users (1.09 ;95%CI = 0.99-1.21 among men and 1.15; 95%CI = 1.00-1.33 among women). The risk for women consuming more than 1 can/day was twice as high as among non-users of tobacco. Current smoking was negatively associated with risk of COVID-19 (aRR = 0.68; 95% CI = 0.61-0.75); including hospital admission (aRR = 0.60; 95% CI = 0.47-0.76) and intensive care (aRR = 0.43; 95% CI = 0.21-0.89). The hypothesis of a protective effect of tobacco nicotine on COVID-19 was not supported by the findings. The negative association between smoking and COVID-19 remains unexplained.

Indexed as

COVID-19Tobacco, SmokelessAdultDental ClinicsFemaleHumansMaleNicotineSwedenTobacco UseNicotine

Identifiers

PMID36681700
PMCPMC9862224
OpenAlexW4317659495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.